146 related articles for article (PubMed ID: 37345094)
1. Surgical Interest of an Accurate Real-World Prediction of Primary Systemic Therapy Response in HER2 Breast Cancers.
Sánchez-Méndez JI; Horstmann M; Méndez N; Frías L; Moreno E; Yébenes L; Roca MJ; Hernández A; Martí C
Cancers (Basel); 2023 May; 15(10):. PubMed ID: 37345094
[TBL] [Abstract][Full Text] [Related]
2. Real-world effectiveness of dual HER2 blockade with pertuzumab and trastuzumab for neoadjuvant treatment of HER2-positive early breast cancer (The NEOPETRA Study).
González-Santiago S; Saura C; Ciruelos E; Alonso JL; de la Morena P; Santisteban Eslava M; Gallegos Sancho MI; de Luna A; Dalmau E; Servitja S; Ruiz Borrego M; Chacón JI
Breast Cancer Res Treat; 2020 Nov; 184(2):469-479. PubMed ID: 32876911
[TBL] [Abstract][Full Text] [Related]
3. Magnetic resonance imaging as a predictor of pathologic response in patients treated with neoadjuvant systemic treatment for operable breast cancer. Translational Breast Cancer Research Consortium trial 017.
De Los Santos JF; Cantor A; Amos KD; Forero A; Golshan M; Horton JK; Hudis CA; Hylton NM; McGuire K; Meric-Bernstam F; Meszoely IM; Nanda R; Hwang ES
Cancer; 2013 May; 119(10):1776-83. PubMed ID: 23436342
[TBL] [Abstract][Full Text] [Related]
4. Real-world data on breast pathologic complete response and disease-free survival after neoadjuvant chemotherapy for hormone receptor-positive, human epidermal growth factor receptor-2-negative breast cancer: a multicenter, retrospective study in China.
Guan D; Jie Q; Wu Y; Xu Y; Hong W; Meng X
World J Surg Oncol; 2022 Sep; 20(1):326. PubMed ID: 36175898
[TBL] [Abstract][Full Text] [Related]
5. The diagnostic accuracy of magnetic resonance imaging in predicting pathologic complete response after neoadjuvant chemotherapy in patients with different molecular subtypes of breast cancer.
Zhang X; Wang D; Liu Z; Wang Z; Li Q; Xu H; Zhang B; Liu T; Jin F
Quant Imaging Med Surg; 2020 Jan; 10(1):197-210. PubMed ID: 31956542
[TBL] [Abstract][Full Text] [Related]
6. Response evaluation after primary systemic therapy of Her2 positive breast cancer – an observational cross-sectional study.
Tőkés T; Szentmártoni G; Torgyík L; Kajáry K; Lengyel Z; Györke T; Molnár BÁ; Tőkés AM; Kulka J; Dank M
Croat Med J; 2015 Apr; 56(2):128-38. PubMed ID: 25891872
[TBL] [Abstract][Full Text] [Related]
7. Discrepancies Between Pathological Tumor Responses and Estimations of Complete Response by Magnetic Resonance Imaging After Neoadjuvant Chemotherapy Differ by Breast Cancer Subtype.
Namura M; Tsunoda H; Yagata H; Hayashi N; Yoshida A; Morishita E; Takei J; Suzuki K; Yamauchi H
Clin Breast Cancer; 2018 Apr; 18(2):128-134. PubMed ID: 28843513
[TBL] [Abstract][Full Text] [Related]
8. Impact of Human Epidermal Growth Factor Receptor 2 (HER2) Low Status in Response to Neoadjuvant Chemotherapy in Early Breast Cancer.
Alves FR; Gil L; Vasconcelos de Matos L; Baleiras A; Vasques C; Neves MT; Ferreira A; Fontes-Sousa M; Miranda H; Martins A
Cureus; 2022 Feb; 14(2):e22330. PubMed ID: 35371692
[TBL] [Abstract][Full Text] [Related]
9. Morphological and pathological response in primary systemic therapy of patients with breast cancer and the prediction of disease free survival: a single center observational study.
Szentmartoni G; Tokes AM; Tokes T; Somlai K; Szasz AM; Torgyík L; Kulka J; Dank M
Croat Med J; 2016 Apr; 57(2):131-9. PubMed ID: 27106355
[TBL] [Abstract][Full Text] [Related]
10. Serum HER2 levels predict treatment efficacy and prognosis in patients with HER2-positive breast cancer undergoing neoadjuvant treatment.
Zuo WJ; He M; Zheng H; Liu Y; Liu XY; Jiang YZ; Wang ZH; Lu RQ; Shao ZM
Gland Surg; 2021 Apr; 10(4):1300-1314. PubMed ID: 33968682
[TBL] [Abstract][Full Text] [Related]
11. Clinical and pathological portraits of axillary presentation breast cancer and effects of preoperative systemic therapy.
Xu L; Li F; Liu Y; Duan X; Ye J; Cheng Y; Xin L
Chin J Cancer Res; 2017 Aug; 29(4):369-373. PubMed ID: 28947869
[TBL] [Abstract][Full Text] [Related]
12. HER2-low status may predict poor neoadjuvant chemotherapy response in HR-negative breast cancer: a real-world multicenter study.
Xu W; Jiang Y; Xu L; Li C; Wang J; Liu Z; Xue D; Gu Y; Zhong Z; He S; Wang S; Zhou W; Pan H
Jpn J Clin Oncol; 2023 Jun; 53(6):463-471. PubMed ID: 36757139
[TBL] [Abstract][Full Text] [Related]
13. Ki67 and lymphocytes in the pretherapeutic core biopsy of primary invasive breast cancer: positive markers of therapy response prediction and superior survival.
Schlotter CM; Tietze L; Vogt U; Heinsen CV; Hahn A
Horm Mol Biol Clin Investig; 2017 Sep; 32(2):. PubMed ID: 28937963
[TBL] [Abstract][Full Text] [Related]
14. Sentinel node biopsy after primary systemic therapy in node positive breast cancer patients: Time trend, imaging staging power and nodal downstaging according to molecular subtype.
Di Micco R; Zuber V; Fiacco E; Carriero F; Gattuso MI; Nazzaro L; Panizza P; Gianolli L; Canevari C; Di Muzio N; Pasetti M; Sassi I; Zambetti M; Gentilini OD
Eur J Surg Oncol; 2019 Jun; 45(6):969-975. PubMed ID: 30744944
[TBL] [Abstract][Full Text] [Related]
15. Pre-treatment MRI tumor features and post-treatment mammographic findings: may they contribute to refining the prediction of pathologic complete response in post-neoadjuvant breast cancer patients with radiologic complete response on MRI?
Thompson BM; Chala LF; Shimizu C; Mano MS; Filassi JR; Geyer FC; Torres US; de Mello GGN; da Costa Leite C
Eur Radiol; 2022 Mar; 32(3):1663-1675. PubMed ID: 34716780
[TBL] [Abstract][Full Text] [Related]
16. Prediction of pathologic complete response on MRI in patients with breast cancer receiving neoadjuvant chemotherapy according to molecular subtypes.
Kim J; Han BK; Ko EY; Ko ES; Choi JS; Park KW
Eur Radiol; 2022 Jun; 32(6):4056-4066. PubMed ID: 34989844
[TBL] [Abstract][Full Text] [Related]
17. Identifying pathologic complete response of the breast after neoadjuvant systemic therapy with ultrasound guided biopsy to eventually omit surgery: Study design and feasibility of the MICRA trial (Minimally Invasive Complete Response Assessment).
van der Noordaa MEM; van Duijnhoven FH; Loo CE; van Werkhoven E; van de Vijver KK; Wiersma T; Winter-Warnars HAO; Sonke GS; Vrancken Peeters MTFD
Breast; 2018 Aug; 40():76-81. PubMed ID: 29698928
[TBL] [Abstract][Full Text] [Related]
18. Overview of resistance to systemic therapy in patients with breast cancer.
Gonzalez-Angulo AM; Morales-Vasquez F; Hortobagyi GN
Adv Exp Med Biol; 2007; 608():1-22. PubMed ID: 17993229
[TBL] [Abstract][Full Text] [Related]
19. Evaluation of MRI accuracy after primary systemic therapy in breast cancer patients considering tumor biology: optimizing the surgical planning.
Bouzón A; Iglesias Á; Acea B; Mosquera C; Santiago P; Mosquera J
Radiol Oncol; 2019 May; 53(2):171-177. PubMed ID: 31104001
[TBL] [Abstract][Full Text] [Related]
20. Predictive and Prognostic Role of Tumor-Infiltrating Lymphocytes in Patients with Advanced Breast Cancer Treated with Primary Systemic Therapy.
Agarwal G; Vishvak Chanthar KMM; Katiyar S; Kumari N; Krishnani N; Sabaretnam M; Chand G; Mishra A; Lal P
World J Surg; 2023 May; 47(5):1238-1246. PubMed ID: 36735048
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
